Omrix Crosseal Promotions Lack Proper Risk Information – Warning Letter
This article was originally published in The Gray Sheet
Executive Summary
An Omrix Crosseal convention panel must include risk information even though the company provided the package insert close at hand, a warning letter from CBER's ad division indicates
You may also be interested in...
Non-Bovine Fibrin Sealant Launches In U.S.; Red Cross To Distribute Crosseal
American Red Cross Plasma Services' three U.S. distributors will ship Omrix Biopharmaceuticals' Crosseal fibrin sealant to liver surgeons throughout the summer
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.